185 related articles for article (PubMed ID: 20805393)
1. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Young TP; Parkin NT; Stawiski E; Pilot-Matias T; Trinh R; Kempf DJ; Norton M
Antimicrob Agents Chemother; 2010 Nov; 54(11):4903-6. PubMed ID: 20805393
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease mutations and protease inhibitor cross-resistance.
Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
[TBL] [Abstract][Full Text] [Related]
3. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
4. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
5. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Desbois D; Roquebert B; Peytavin G; Damond F; Collin G; Bénard A; Campa P; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2008 Apr; 52(4):1545-8. PubMed ID: 18227188
[TBL] [Abstract][Full Text] [Related]
6. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
Santos JR; Llibre JM; Imaz A; Domingo P; Iribarren JA; Mariño A; Miralles C; Galindo MJ; Ornelas A; Moreno S; Schapiro JM; Clotet B;
J Antimicrob Chemother; 2012 Jun; 67(6):1462-9. PubMed ID: 22431669
[TBL] [Abstract][Full Text] [Related]
8. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
Poveda E; de Mendoza C; Martin-Carbonero L; Corral A; Briz V; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
[TBL] [Abstract][Full Text] [Related]
12. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
[TBL] [Abstract][Full Text] [Related]
13. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Eche S; Kumar A; Sonela N; Gordon ML
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
[TBL] [Abstract][Full Text] [Related]
14. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
Raugi DN; Smith RA; Ba S; Toure M; Traore F; Sall F; Pan C; Blankenship L; Montano A; Olson J; Dia Badiane NM; Mullins JI; Kiviat NB; Hawes SE; Sow PS; Gottlieb GS;
Antimicrob Agents Chemother; 2013 Jun; 57(6):2751-60. PubMed ID: 23571535
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
16. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
Parkin NT; Chappey C; Petropoulos CJ
AIDS; 2003 May; 17(7):955-61. PubMed ID: 12700444
[TBL] [Abstract][Full Text] [Related]
17. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
18. Both a protective and a deleterious role for the L76V mutation.
Tartaglia A; Saracino A; Monno L; Tinelli C; Angarano G
Antimicrob Agents Chemother; 2009 Apr; 53(4):1724-5. PubMed ID: 19299521
[No Abstract] [Full Text] [Related]
19. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V; Ceccherini-Silberstein F; Erba F; Santoro M; Gori C; Bellocchi MC; Giannella S; Trotta MP; Monforte Ad; Antinori A; Perno CF
Antimicrob Agents Chemother; 2005 May; 49(5):2015-25. PubMed ID: 15855527
[TBL] [Abstract][Full Text] [Related]
20. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
